

CoRE Scientific Conference

Patients as Partners for Health:

Co-Creating Equitable Access to Health Products and Services

5 - 6 October 2022

8.30 am to 4.30 pm SGT

Day 1 – 5 October, Wednesday Topic **Speaker/ Organisation** Registration 8.30 am Welcome remarks by Scientific Chair 9.00 am Adj Prof John Skerritt Adjunct Professor, University of Sydney Deputy Secretary, Australian Department of Health Special Advisor, CoRE Advisory Board Australia 9.10 am Welcome remarks by Scientific Vice Chair **Dr Lembit Rago** Secretary-General Council for International Organizations of Medical Sciences (CIOMS) Switzerland 9.15 am **Opening speech by Guest of Honour Dr Janil Puthucheary** Senior Minister of State Ministry of Communications and Information & Ministry of Health Singapore 9.30 am Plenary I - Patients as Active Partners in The Session chair **Development, Regulation, and Use of Medicines Prof John Lim Executive Director** Centre of Regulatory Excellence (CoRE) **Duke-NUS Medical School** Singapore Speakers & Panellists **Dr Margaret Hamburg** Chair, CoRE Advisory Board Former Commissioner U.S. Food And Drug Administration United States of America Dr Juan Garcia Burgos Head Public and Stakeholders **Engagement Department** Stakeholders and Communication Division European Medicines Agency (EMA) The Netherlands Dr Yasuhiro Fujiwara Chief Executive Pharmaceuticals and Medical Devices Agency Japan



Director Treatment Information and Access European Organisation for Rare Diseases (EURORDDS) France 10.45 am Session 1 – Preclinical and Clinical Development 20.45 am Session 1 – Preclinical and Clinical Development 20.45 am Session 1 – Preclinical and Clinical Development 20.45 am Session 1 – Preclinical and Clinical Development 20.45 am Session 1 – Preclinical and Clinical Development 20.45 am Session 1 – Preclinical and Clinical Development 20.45 am Session 2 – Preclinical and Clinical Development 20.45 am Session 2 – Benefit and Risk Assessment 20.45 am Session 2 – Benefit and Risk Assessment			Mr François Houÿez
10.30 am Tea Break 10.45 am Session 1 - Preclinical and Clinical Development Session 1 - Preclinical and Clinical Development Session Chair Dr Joseph Scheeren Scheeren HealthCare LLC Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Special Advisor, Former President and Chief Executive Officer Officer Officer Path Operations and Site Engagement Boehringer Ingelheim Germany Ms Helen Green Senior Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houýez Director Treatment Information and Access (EURORDIS) France 11.45 am Session 2 - Benefit and Risk Assessment Session 2 - Benefit and Risk Assessment Session Chair Mr Michael Groop Member CoRE Advisory Board United States of America			
10.30 am Tea Break 10.45 am Session 1 - Preclinical and Clinical Development Session Chair Dr Joseph Scheeren Founder Scheeren HealthCare LLC Special Advisor, Former President and Chief Executive Officer Scheeren HealthCare LLC Special Advisor, Former President and Chief Executive Officer Dr Joseph Scheeren Founder Scheeren HealthCare LLC Special Advisor, Former President and Chief Executive Officer Dr Joseph Scheeren Scheeren HealthCare LLC Dr Joseph Scheeren Scheeren HealthCare LLC Dr Kimberley Kallsen Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Ms Helen Green Senior Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access (EURORDIS) France 11.45 am Session 2 - Benefit and Risk Assessment			
(EURORDIS) France 10.45 am Session 1 - Preclinical and Clinical Development Session 1 - Preclinical and Clinical Development Session Chair Dr Joseph Scheeren Scheeren HealthCare LLC Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Speakers & Panellists Dr Joseph Scheeren Scheeren HealthCare LLC Speakers & Panellists Dr Joseph Scheeren Scheeren HealthCare LLC Dr Kimberley Kallsen Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Ms Helen Green Serier Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houiyez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 - Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
10.30 am Tea Break 10.45 am Session 1 - Preclinical and Clinical Development Session Chair Dr Joseph Scheeren Founder Scheeren HealthCare LLC Special Advisor, Former President and Chief Executive Officer Special Advisor, Former President and Chief Executive Officer Ortical Path Institute (C-Path) United States of America Speakers & Panellists Dr Joseph Scheeren Scheeren HealthCare LLC Dr Kimberley Kallson Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Ms Helen Green Senior Director Senior Director Patient Experience Syneos Health Mr Jan Geissler Founder and CEO Patvocates Germany Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 - Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
10.30 am Tea Break 10.45 am Session 1 - Preclinical and Clinical Development Session Chair Dr Joseph Scheeren Founder Scheeren HealthCare LLC Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Speakers & Panellists Dr Joseph Scheeren Scheeren HealthCare LLC Speakers & Panellists Dr Joseph Scheeren Scheeren HealthCare LLC Dr Kimberley Kallsen Head of Global Clinical Development and Operations and Site Engagement Boshringer Ingelheim Germany Ms Helen Green Senior Director Senior Director Patient Experience Synces Health Mither Green Senior Director Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 - Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
10.45 am Session 1 - Preclinical and Clinical Development Session Chair Dr. Joseph Scheeren Founder Scheeren HealthCare LLC Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Scheeren HealthCare LLC Dr Value Advisor, Former President and Comparison on Stite Engagement Boehringer Ingelheim Germany Mister Path Institute (C-Path) United Kingdom Panellists Mr Jan Geissler Founder and CEO Patwocates Germany Mr François Houÿez Director Tratement Information and Access European Organistation for Rare Diseas			France
10.45 am Session 1 - Preclinical and Clinical Development Session Chair Dr. Joseph Scheeren Founder Scheeren HealthCare LLC Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Special Advisor, Former President and Comparison of Stie Engagement Boehringer Ingelheim Germany Ms Helen Green Sension Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geiseler Founder and CEO Pation Care Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France Session Chair M	10.20 om		
Dr. Joseph Scheeren Founder Scheeren HealthCare LLC Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Speakers & Panellists Dr Joseph Scheeren Scheeren HealthCare LLC Dr Kimberley Kallsen Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Mis Helen Green Senior Director Patient Experience Synces Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			Socian Chair
Founder Scheeren HealthCare LLC Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Speakers & Panellists Dr Joseph Scheeren Dr Joseph Scheeren HealthCare LLC Dr Kimberley Kallsen Head of Global Clinical Development and Operations and Stite Engagement Bochninger Ingelheim Germany Ms Helen Green Pathinger Ingelheim Germany Ms Helen Green Senior Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patternet Information and Access European Organisation for Rare Diseases European Organisation for Rare Diseases EURORDIS) France Session 2 - Benefit and Risk Assessment Session Chair Mr Michael Groep Member CoRE Advisory Board United States of America Session Chair	10.45 am	Session 1 – Precimical and Chinical Development	
Scheeren HealthCare LLC Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Scheeren HealthCare LLC Dr Kimberley Kallsen Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Ms Helen Green Senior Director Patient Experience Syneos Health United Kingdom Patient Experience Syneos Health United Kingdom Patient Experience Syneos Health United Kingdom Parellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EUR RORDIS) France 11.45 am Session 2 - Benefit and Risk Assessment			
Special Advisor, Former President and Chief Executive Officer Critical Path Institute (C-Path) United States of America Speakers & Panellists Dr Joseph Scheeren Scheeren HealthCare LLC Dr Kimberley Kallsen Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Mis Helen Green Senior Director Patient Experience Syneos Health United Kingdom Panellists Mir Jan Geissler Founder and CEO Patternt Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 - Benefit and Risk Assessment Session Chair Mir Michael Groep Member CoRE Advisory Board United States of America			
Executive Officer Critical Path Institute (C-Path) United States of America Speakers & Panellists Dr Joseph Scheeren Scheeren HealthCare LLC Dr Kimberley Kallsen Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Ms Helen Green Senior Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Infector Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CORE Advisory Board United States of America			
Critical Path Institute (C-Path) United States of America Speakers & Panellists Dr Joseph Scheeren Scheeren HealthCare LLC Dr Kimberley Kallsen Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Ms Helen Green Senior Director Patienence Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 - Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
United States of America Speakers & Panellists Dr Joseph Scheeren Scheeren HealthCare LLC Dr Kimberley Kallsen Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Ms Helen Green Senico Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
Speakers & Panellists Dr Joseph Scheeren Scheeren HealthCare LLC Dr Kimberley Kallsen Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Ms Helen Green Senior Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 - Benefit and Risk Assessment Session Chair Mr Michael Groop Member CoRE Advisory Board United States of America			
Dr Joseph Scheeren Scheeren HealthCare LLC Dr Kimberley Kallsen Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Ms Helen Green Senior Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			United States of America
Dr Joseph Scheeren Scheeren HealthCare LLC Dr Kimberley Kallsen Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Ms Helen Green Senior Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseasess (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			Spoakors & Danollists
Scheeren HealthCare LLC Dr Kimberley Kallsen Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Ms Helen Green Senior Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
Dr Kimberley Kallsen Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Ms Helen Green Senior Director Patient Experience Syneos Health United Kingdom Panelists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Ms Helen Green Senior Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			Scheelen healthCare LEC
Head of Global Clinical Development and Operations and Site Engagement Boehringer Ingelheim Germany Ms Helen Green Senior Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			Dr Kimberlev Kallsen
Operations and Site Engagement Boehringer Ingelheim Germany Ms Helen Green Senior Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 - Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
Boehringer Ingelheim Germany Boehringer Ingelheim Germany Ms Helen Green Senior Director Patient Experience Syneos Health United Kingdom Senior Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
Germany Ms Helen Green Senior Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
Ms Helen Green Senior Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France France			
Senior Director Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France France 11.45 am Session 2 - Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			Connary
Patient Experience Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 - Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America Vinited States of America			Ms Helen Green
Syneos Health United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			Senior Director
United Kingdom Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			Patient Experience
Panellists Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			Syneos Health
Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			United Kingdom
Mr Jan Geissler Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			Demoliate
Founder and CEO Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
Patvocates Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
Germany Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
Mr François Houÿez Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			Germany
Director Treatment Information and Access European Organisation for Rare Diseases (EURORDIS) France France 11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			Mr Francois Houÿez
11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
11.45 am Session 2 – Benefit and Risk Assessment Session Chair Mr Michael Gropp Member CoRE Advisory Board United States of America			
The image is a set of the image is			
Mr Michael Gropp Member CoRE Advisory Board United States of America			
Mr Michael Gropp Member CoRE Advisory Board United States of America			
Member CoRE Advisory Board United States of America	11.45 am	Session 2 – Benefit and Risk Assessment	
CoRE Advisory Board United States of America			
United States of America			
Speaker & Panellists			United States of America
Opeaner & ranemsis			Sneaker & Panellists
Ms Marilyn Metcalf			
Senior Director			
Patient Engagement			
Fallent Engagement	L		



		0.01/
		GSK United States of America
		Dr Iris Conela Tagaro
		Head, Clinical Research Section
		FDA Philippines
		Panellists
		Dra Rr Maya Gustina Andarini
		Deputy for Control of Drugs, Narcotics,
		Psychotropics, Precursors and Addictive
		Substances
		Badan POM Indonesia
		Dr Marca Crass
		Dr Marco Greco President
		European Patients' Forum
12.45 pm	Lunch	
1.00 pm	Lunch Talk: Unlocking the Potential of Gene Therapy for Rare Diseases	Sponsored by Pfizer
2.00 pm	Session 3 – HTA and Access	Session chair
		Ms Fiona Pearce
		Senior Advisor
		HTA and Consumer Engagement and Education
		Agency for Care Effectiveness (ACE)
		Ministry of Health
		Singapore
		Speakers & Panellists
		Ms Ann Single
		Chair
		HTAi Patient and Citizen Involvement in HTA
		Interest Group
		Coordinator/Advisory Committee Member Patient
		Voice Initiative Australia
		Australia
		Dr Annabelle Borromeo
		Director
		The Centre for Nurse Impact and Patient
		Outcomes Action Lab
		Philippines
		Dr Sophie Werkö
		Manager International Relations & Patient
1		Engagement
		SBU, Swedish Council on Health Technology
		Assessment
		Sweden
		Panellists
1		Dr Yot Teerawattananon
		Founder
6		



		Thai Ministry of Public Health's Health Intervention & Technology Assessment Program (HITAP) Co-founder, Asia's Health Technology Assessment (HTA) Network (HTAsiaLink) & International Decision Support Initiative (iDSI) Thailand
		Mr Richard Vines Founder and Chairman
		Rare Cancers Australia
3.00pm	Tea Break	
3.15 pm	Session 4 – Communication in Safety and Healthcare Delivery	<u>Session chair</u> Dr Juan Garcia Burgos EMA
		<u>Speakers & Panellists</u> Dr Juan Garcia Burgos EMA
		Ms Ai Ling Sim-Devadas Patient Mentor SingHealth Patient Advocacy Network (SPAN) Global Patient and Family Advisory Board Member Beryl Institute Singapore
		Ms Adena Lim Deputy Director (Vigilance & Compliance) Health Sciences Authority (HSA) Singapore
		Dr Marco Greco President European Patients' Forum
4.30pm	End of Day 1	

Day 2 - 6 October, Thursday

	Торіс	Speaker/ Organisation
9.00 am	Plenary II – Putting the Patient at the Forefront of	Session Chair
	Patient Engagement	Mr Rajakanth R
		Principal Consultant
		Manifeste LLP
		Executive Director
		Rainbow Across Borders Ltd
		Singapore
		Speakers & Panellists
		Prof Carmencita D Padilla
		College of Medicine
		University of Philippines
		Dr Elisabeth Oehrlein



Centre of	
Centre of Regulatory Excellence	
5	

Founder and CEO Applied Patient Experience, LLC United States of America Adj Prof Tarun Weoramanthri President President Public Health Association of Australia Governing Council, World Federation of Public 9.50 am Session 5 – Strengthening the Culture of Patient Engagement in Health Systems in the Region Session chair Michi Swarup Founder and President Crohn's and Colitis Society of Singapore Speakers & Panellists Mr Rajakanth R Rainbow Across Borders Ltd Ms Nichi Swarup Crohn's and Colitis Society of Singapore Speakers & Panellists Mr Rajakanth R Mr Rajakanth R Rainbow Across Borders Ltd Ms Nichi Swarup Crohn's and Colitis Society of Singapore Panellists Mr Rajakanth R Microbid Speciality Care Public Affairs House068 (China Lymphoma Patient Group) China Ms Doreen Tan Global Speciality Care Public Affairs Lead Motal Speciality Care Public Affairs Lead For Unitermational Affairs Mitonal Agency of Food and Drug Control Indonesia 10.55 am Session 6 – Using Patient-Generated Health Data Session Chair (PGHD) and Real-World Evidence (RWE) to Accelerate Patien			
9.50 am Session 5 – Strengthening the Culture of Patient Engagement in Health Systems in the Region Session chair Ms Nidhi Swarup Crohn's and Colitis Society of Singapore 9.50 am Session 5 – Strengthening the Culture of Patient Engagement in Health Systems in the Region Session chair Ms Nidhi Swarup Crohn's and Colitis Society of Singapore 9.50 am Session Chair Ms Nidhi Swarup Crohn's and Colitis Society of Singapore Speakers & Panellists Ms Rajkanth R Rainbow Across Borders Ltd Ms Nidhi Swarup Crohn's and Colitis Society of Singapore Speakers & Panellists Ms Colitis Society of Singapore Panellists Ms Johny Zhang Director of International Affairs House086 (China Lymphoma Patient Group) China Sanoti Malaysia 10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement 10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement 10.55 am Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Eviders, Inc. PPD, a part of Thermo Fisher Scientific Adj prof Meredith Smith Scient Of Thermacy University of Southern California			Founder and CEO
 Adj Prof Tarun Weeramanthri President Public Health Association of Australia Governing Council, World Federation of Public Health Association 9.50 am Session 5 – Strengthening the Culture of Patient Engagement in Health Systems in the Region 9.50 am Session Chair Ms Nichl Swarup Founder and President Crohn's and Colitis Society of Singapore Speakers 8 Panellists Mr Rajakanth R Rainbow Across Borders Ltd Ms Nichl Swarup Founder and President Crohn's and Colitis Society of Singapore Speakers 8 Panellists Mr Rajakant R Rainbow Across Borders Ltd Ms Nichl Swarup Crohn's and Colitis Society of Singapore Panellists Ms John Swarup Crohn's and Colitis Society of Singapore Panellists Ms John Swarup Crohn's and Colitis Society of Singapore Panellists Ms John Systems House086 (China Lymphoma Patient Group) China Ms Doreen Tan Global Specialty Care Public Affairs Lead for China and International Sanofi Malaysia Pan Lucky Slamet Former Head National Agency of Food and Drug Control Indonesia Magency of Food and Drug Control Indonesia Malaysia Passion Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Profeesor Spoakers & Panellists 			
10.40 am Tea Break 10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data 10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data 10.40 am Tea Break			United States of America
10.40 am Tea Break 10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data 10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data 10.40 am Tea Break			Adi Prof Tarun Weeramanthri
9.50 am Session 5 - Strengthening the Culture of Patient Session chair 9.50 am Session 5 - Strengthening the Culture of Patient Session chair Founder and President Session chair Session chair Ms Nidhi Swarup Founder and President Crohn's and Colitis Society of Singapore Sheet of President Crohn's and Colitis Society of Singapore Sheet of Singapore Sheet of China Colitis Society of Singapore Session chair Ms Nidhi Swarup Crohn's and Colitis Society of Singapore Sheet of International Affairs Ms Jenny Zhang Director of International Affairs House086 (China Lymphoma Patient Group) China Ms Joneen Tan Global Specialty Care Public Affairs Lead tor China and International Sanofi Malaysia Dra Lucky Slamet Former Head National Agency of Food and Drug Control Indonesia Maloresia 10.55 am Session 6 - Using Patient-Generated Health Data Session Chair Adj Prof Meredith Smith Senior Director Maloysia Dra Lucky Slamet Former Head Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Indonesia Senior Director Proherer AssersConchair Adj Prof Mere			
9.50 am Session 5 – Strengthening the Culture of Patient Engagement in Health Systems in the Region Session chair Ms Nidhi Swarup Founder and President Crohn's and Colitis Society of Singapore 9.50 am Session 5 – Strengthening the Culture of Patient Engagement in Health Systems in the Region Session chair Ms Nidhi Swarup Founder and President Crohn's and Colitis Society of Singapore 9.50 am Session 5 – Strengthening the Culture of Patient Engagement in Health Systems in the Region Session chair Ms Nidhi Swarup Founder and President Crohn's and Colitis Society of Singapore 9.50 am Session Chair Ms Nidhi Swarup Crohn's and Colitis Society of Singapore 9.50 am Session Chair Ms Nidhi Swarup Crohn's and Colitis Society of Singapore 9.50 am Session Chair Ms Nidhi Swarup Crohn's and Colitis Society of Singapore 9.50 am Tea Break 10.40 am Tea Break 10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data (PCHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a pat of Thermo Fisher Scientific Adj Prof Meredith Smith Speckers & Panellists Adj Prof Meredith Smith			
 Health Association School of Population and Global Health University of Western Australia 9.50 am Session 5 - Strengthening the Culture of Patient Engagement in Health Systems in the Region Session chair Ms Nidhi Swarup Founder and President Crohn's and Colitis Society of Singapore Speakers & Panellists Mr Rajakanth R Rainbow Across Borders Ltd Ms Nidhi Swarup Crohn's and Colitis Society of Singapore Panellists Ms Alenny Zhang Director of International Affairs House086 (China Lymphoma Patient Group) China Ms Doreen Tan Global Specialty Care Public Affairs Lead for China and International Sanofi Malaysia Dra Lucky Slamet Former Head National Agency of Food and Drug Control Indonesia 10.40 am Tea Break Session 6 - Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session 7 - Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Sensor Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adj Prof Meredith Smith 			
9.50 am Session 5 – Strengthening the Culture of Patient Engagement in Health Systems in the Region Session chair Ms Nidh i Swarup Founder and President Crohn's and Colitis Society of Singapore 9.50 am Session 4 dollard Society of Singapore Speakers & Panellists Mr Rajakanth R Rainbow Across Borders Ltd Ms Nidh i Swarup Founder and President Crohn's and Colitis Society of Singapore 9.60 am Teal Break Ms Nidh i Swarup Crohn's and Colitis Society of Singapore 9.61 amount of the second			-
9.50 am Session 5 - Strengthening the Culture of Patient Engagement in Health Systems in the Region Session chair Ms Nidhi Swarup Founder and President Crohn's and Colitis Society of Singapore Speakers & Panellists Mr Rajakanth R Rainbow Across Borders Ltd Ms Nidhi Swarup Crohn's and Colitis Society of Singapore Panellists Mr Brand President Crohn's and Colitis Society of Singapore Panellists Ms Jenny Zhang Director of International Affairs House086 (China Lymphoma Patient Group) China 10.40 am Tea Break 10.55 am Session 6 - Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement 10.55 am Session 6 - Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement 10.40 am Tea Break Session Chair Adj Prof Meredith Smith Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adj Prof Meredith Smith School of Pharmacy University of Southern California			
9.50 am Session 5 - Strengthening the Culture of Patient Engagement in Health Systems in the Region Session chair Ms Nidhi Swarup Founder and President Crohn's and Colitis Society of Singapore 9.50 am Speakers & Panellists Mr Rajakanth R Rainbow Across Borders Ltd Ms Nidhi Swarup Crohn's and Colitis Society of Singapore 9.60 am No Nidhi Swarup Crohn's and Colitis Society of Singapore Panellists Mr Rajakanth R Rainbow Across Borders Ltd Ms Nidhi Swarup Crohn's and Colitis Society of Singapore Panellists Ms Jenny Zhang Director of Intermational Affairs House068 (China Lymphoma Patient Group) China Ms Doreen Tan Global Specialty Care Public Affairs Lead for China and International Sanofi Malaysia Ms Doreen Tan Global Specialty Care Public Affairs Lead for China and International Sanofi Malaysia 10.55 am Session 6 - Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Servico Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjurct Professor School of Pharmacy University of Southern California Speckers & Panellists Adj Prof Meredith Smith Speckers & Panellists Adj Prof Meredith Smith			•
Engagement in Health Systems in the Region Ms Nidhi Swarup Founder and President Crhn's and Colitis Society of Singapore Speakers & Panellists Mr Rajakanth R Rainbow Across Borders Ltd Ms Nidhi Swarup Crhn's and Colitis Society of Singapore Panellists Ms Nidhi Swarup Crhn's and Colitis Society of Singapore Ms Nidhi Swarup Crhn's and Colitis Society of Singapore Panellists Ms Jenny Zhang Director of Intermational Affairs House080 (China Lymphoma Patient Group) China Ms Joneen Tan Global Specialty Care Public Affairs Lead tor China and International Sanoti 10.40 am Tea Break 10.55 am Session 6 - Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senico Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adj Prof Meredith Smith Serici Director Implementation Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adj Prof Meredith Smith Science Caroup Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adj Prof Meredith Smith Science Caroup Lead Patient-Centered Research Evidera, Inc.			
 Founder and President Crohn's and Colitis Society of Singapore Speakers & Panellists Mr Rajakanth R Rainbow Across Borders Ltd Ms Nidhi Swarup Crohn's and Colitis Society of Singapore Panellists Ms Jenny Zhang Director of International Affairs House086 (China Lymphoma Patient Group) China Ms Doreen Tan Giobal Specialty Care Public Affairs Lead for China and International Sanofi Malaysia Dra Lucky Slamet Former Head National Agency of Food and Drug Control Indonesia Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjur of Thermo Fisher Scientific Adjur Of Thermo Fisher Scientific Adjur Of Thermo Fisher Scientific Adjur Of Southern California Speakers & Panellists Adj Prof Meredith Smith 	9.50 am	Session 5 – Strengthening the Culture of Patient	Session chair
 Crohn's and Colitis Society of Singapore Speakers & Panellists Mr Rajakanth R Rainbow Across Borders Ltd Ms Nidhi Swarup Crohn's and Colitis Society of Singapore Panellists Ms Jenny Zhang Director of International Affairs House086 (China Lymphoma Patient Group) China Ms Doreen Tan Global Specialty Care Public Affairs Lead for China and International Sanofi Malaysia Dra Lucky Slamet Former Head National Agency of Food and Drug Control Indonesia 10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adj Prof Mereditis Smith 		Engagement in Health Systems in the Region	
 Speakers & Panellists Mr Rajakanth R Rainbow Across Borders Ltd Ms Nichi Swarup Crohn's and Colitis Society of Singapore Panellists Ms Jenny Zhang Director of International Affairs House086 (China Lymphoma Patient Group) China Ms Doreen Tan Global Specialty Care Public Affairs Lead for China and International Sanofi Malaysia Dra Lucky Slamet Former Head National Agency of Food and Drug Control Indonesia 10.40 am Tea Break Session Chair Accelerate Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Science Group Lead Patient-Centered Research Evidera, Inc: PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith 			
10.40 am Tea Break 10.55 am Session 6 - Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Zhareg Director of International Session Science Group Lead Patient-Centered Research Evidera, Inc. PD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California			Crohn's and Colitis Society of Singapore
10.40 am Tea Break 10.55 am Session 6 - Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Zhareg Director of International Session Science Group Lead Patient-Centered Research Evidera, Inc. PD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California			Spoakors & Papallists
 Rainbow Across Borders Ltd Ms Nidhi Swarup Crohn's and Colitis Society of Singapore Panellists Ms Jenny Zhang Director of International Affairs House086 (China Lymphoma Patient Group) China Ms Doreen Tan Global Specialty Care Public Affairs Lead for China and International Sanofi Malaysia Dra Lucky Slamet Former Head National Agency of Food and Drug Control Indonesia 10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith 			
10.40 am Tea Break 10.55 am Session 6 - Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. 10.40 am Tea Break			
 Crohn's and Colitis Society of Singapore Panellists Ms Jenny Zhang Director of International Affairs House086 (China Lymphoma Patient Group) China Ms Doreen Tan Global Specialty Care Public Affairs Lead for China and International Sanofi Malaysia Dra Lucky Slamet Former Head National Agency of Food and Drug Control Indonesia 10.40 am Tea Break Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southerm California Speakers & Panellists Adj Prof Meredith Smith 			Nambow Across Dorders Eld
 Crohn's and Colitis Society of Singapore Panellists Ms Jenny Zhang Director of International Affairs House086 (China Lymphoma Patient Group) China Ms Doreen Tan Global Specialty Care Public Affairs Lead for China and International Sanofi Malaysia Dra Lucky Slamet Former Head National Agency of Food and Drug Control Indonesia 10.40 am Tea Break Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southerm California Speakers & Panellists Adj Prof Meredith Smith 			Ms Nidhi Swarup
10.40 am Tea Break 10.55 am Session 6 - Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Pat of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California			
10.40 am Tea Break 10.55 am Session 6 - Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Pat of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California			–
Director of International Affairs House086 (China Lymphoma Patient Group) China Ms Doreen Tan Global Specialty Care Public Affairs Lead for China and International Sanofi Malaysia Dra Lucky Slamet Former Head National Agency of Food and Drug Control Indonesia 10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Sension Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith			
 House086 (China Lymphoma Patient Group) China Ms Doreen Tan Global Specialty Care Public Affairs Lead for China and International Sanofi Malaysia Dra Lucky Slamet Former Head National Agency of Food and Drug Control Indonesia 10.40 am Tea Break Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith 			
China Ms Doreen Tan Global Specialty Care Public Affairs Lead for China and International Sanofi Malaysia 10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement 10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement 20.40 am Tea Break 20.40 am Session Chair Adj Prof Meredith Smith Second of Pharmacy University of Southern California <td< th=""><th></th><th></th><th></th></td<>			
Ms Doreen Tan Global Specialty Care Public Affairs Lead for China and International Sanofi Malaysia Sanofi Malaysia Dra Lucky Slamet Former Head National Agency of Food and Drug Control Indonesia Former Head National Agency of Food and Drug Control Indonesia 10.40 am Tea Break Session 6 - Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith			
Global Specialty Care Public Affairs Lead for China and International Sanofi Malaysia Dra Lucky Slamet Former Head National Agency of Food and Drug Control Indonesia 10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Kerner Head National Agency of Food and Drug Control Indonesia Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith			China
10.40 am Tea Break 10.55 am Session 6 - Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith			Ms Doreen Tan
Sanofi Malaysia Sanofi Malaysia Dra Lucky Slamet Former Head National Agency of Food and Drug Control Indonesia 10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith			Global Specialty Care Public Affairs Lead
Malaysia Dra Lucky Slamet Former Head National Agency of Food and Drug Control Indonesia 10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith			for China and International
10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith			Sanofi
10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith			Malaysia
10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith			Dro Lucky Clamat
10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith			•
10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith			
10.40 am Tea Break 10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith			• • •
10.55 am Session 6 – Using Patient-Generated Health Data (PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Session Chair Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith			machesia
(PGHD) and Real-World Evidence (RWE) to Accelerate Patient Engagement Adj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith	10.40 am	Tea Break	
(PGHD) and Real-World Evidence (RWE) to Accelerate Patient EngagementAdj Prof Meredith Smith Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern CaliforniaSpeakers & Panellists Adj Prof Meredith Smith	10.55 am	Session 6 – Using Patient-Generated Health Data	Session Chair
Accelerate Patient Engagement Senior Director Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith Adj Prof Meredith Smith		-	Adj Prof Meredith Smith
Implementation Science Group Lead Patient-Centered Research Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California Speakers & Panellists Adj Prof Meredith Smith			Senior Director
Evidera, Inc. PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California <u>Speakers & Panellists</u> Adj Prof Meredith Smith			
PPD, a part of Thermo Fisher Scientific Adjunct Professor School of Pharmacy University of Southern California <u>Speakers & Panellists</u> Adj Prof Meredith Smith			
Adjunct Professor School of Pharmacy University of Southern California <u>Speakers & Panellists</u> Adj Prof Meredith Smith			
School of Pharmacy University of Southern California <u>Speakers & Panellists</u> Adj Prof Meredith Smith			
University of Southern California <u>Speakers & Panellists</u> Adj Prof Meredith Smith			
Speakers & Panellists Adj Prof Meredith Smith			
Adj Prof Meredith Smith			University of Southern California
Adj Prof Meredith Smith			Speakers & Panellists



		Dr Mehmet Burcu Senior Principal Scientist Epidemiology Merck
		Dr Laura Pizzi Associate Chief Science Officer International Society for Pharmacoeconomics and Outcomes (ISPOR)
		Panellists Dr Soren Skovlund Senior Director, Head, Patient Engagement Patient-Centered Research, Evidera, Inc. PPD, a part of Thermo Fisher Scientific
11.45 am	Session 7 – Development Priorities for Patient Engagement in Asia-Pacific	Session Chair Asst Prof James Leong Head Health Products and Regulatory Science Centre of Regulatory Excellence Duke-NUS Medical School Singapore
		Speakers & Panellists Ms Tan Ping-Tee Senior Specialist Consumer Engagement and Education (CEE) Agency Agency for Care Effectiveness (ACE) Ministry of Health Singapore
		Mr Richard Vines Founder and Chairman Rare Cancers Australia
		Mr Satoshi Miki Board Member Patient and Public Involvement Japan
		Panellists Mr Neil Wildman Senior Director Patient Advocacy Asia Pacific and Africa Middle East Team Lead Pfizer Australia
		Dr Izzuna Mudla Deputy Director Medical Development Division, Ministry of Health Malaysia Head, Malaysian Health Technology Assessment Section (MaHTAS)



Centre of Regulatory Excellence

		Malaysia
12.45 pm 1.00pm	Lunch Lunch Talk: Key findings of the EIU White Paper – Implications for Patient Engagement across Asia- Pacific	Sponsored by Johnson & Johnson
2.00pm	Session 8 – Building and Using Regional Multi- Stakeholder Platforms to Progress Patient Engagement in the Region	Session chair Dr Lembit Rago Secretary-General Council for International Organizations of Medical Sciences (CIOMS) Switzerland
		<u>Speakers & Panellists</u> Dr Lembit Rago CIOMS
		Dr Ritu Jain Co-chair Agency for Care Effectiveness Consumer Panel President, DEBRA International & DEBRA Singapore
		PanellistsDr Jinho ShinMedical Officer/Acting CoordinatorEssential Medicines and Health Technologies(EMT)Division of Health Systems and Services(DHS)World Health Organization Regional Office forthe Western Pacific
		Ms Ranjit Kaur Pritam Singh Immediate Past President, Breast Cancer Welfare Association Malaysia Founding President of Together Against Cancer Association Malaysia Board Member, Reach to Recovery International Board Member, Advanced Breast Cancer Global Alliance
		Dr Nichiren Pillai Medical Affairs Lead Malaysia & Singapore Boehringer Ingelheim Malaysia
3.00pm	Tea Break	
3.15pm	Closing Plenary – Reflecting on the Draft Consensus Statement and Next Steps	Session Chair Adj Prof John Skerritt Adjunct Professor, University of Sydney Deputy Secretary, Australian Department of Health Special Advisor, CoRE Advisory Board



		Australia
		<u>Panellists</u> Prof John Lim CoRE
		Dr Lembit Rago CIOMS
		Mr Ekawat Suwantaroj Committee Hemophilia Foundation of Thailand
		Ms Fatima Lorenzo Co-founder and Board of Advisers Philippine Alliance of Patient Organizations Co-Founder, Kythe Foundation Inc. Philippines
4.30pm	End of Conference	